This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Google Scholar Articles by Mitamura, Y. Articles by Yamamoto, S. PubMed PubMed Citation Articles by Mitamura, Y. Articles by Yamamoto, S.

Retinal detachment with macular hole following intravitreal bevacizumab in patient with severe proliferative diabetic retinopathy

Department of Ophthalmology and Visual Science, Chiba University Graduate School of Medicine, Chiba, Japan

Correspondence to:
Y Mitamura, Department of Ophthalmology and Visual Science, Chiba University Graduate School of Medicine, 1–8–1 Inohana, Chuo-ku, Chiba 260–8670, Japan; ymita@faculty.chiba-u.jp

Accepted 15 February 2008

The first 150 words of the full text of this article appear below.

We read with interest the article by Arevalo et al¹ about the development of a tractional retinal detachment (TRD) following the use of intravitreal bevacizumab (Avastin; Genetech Inc., San Francisco, California, USA) as an adjuvant to vitrectomy for the management of severe proliferative diabetic retinopathy (PDR). They warned that TRD might occur or progress shortly after intravitreal bevacizumab. We present a case of a retinal detachment with macular hole (MH–RD) that developed after intravitreal bevacizumab that was used for neovascular glaucoma as a result of severe PDR.

CASE REPORT
A 40-year-old man with diabetes of 19 years presented with PDR and neovascular glaucoma in the right eye that was refractory to panretinal photocoagulation (PRP). He was being treated with insulin but had poor glycaemic control (HbA1c 10.8%). Initially, his best corrected visual acuity was 0.06 with a –1.5-diopter lens and the intraocular pressure was 48 mm Hg under maximal medication. Anterior segment . . . [Full text of this article]